# Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy

> **NCT01484860** · PHASE2 · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 15 (actual)

## Conditions studied

- Adenocarcinoma of the Pancreas
- Metastatic Disease

## Interventions

- **DRUG:** AUY922

## Key facts

- **NCT ID:** NCT01484860
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01484860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01484860, "Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01484860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*